Stratification of Genomic Sequence Complexity and Phenotypes for Precision Medicine
Statistics-first.No reference genome required.Unbiased discovery.
The website is being updated with additional content. Please contact: BD@rosabio.com for more information.
Single Cell Demo
Sequence-level models, tested on cells they never saw. Every score is on cells, patients or experiments kept out of training.
Results last updated 2026-11-09 15:58 PST
Exhausted vs active killer T cells in patients on immunotherapy
PD-L1 levels in lung tumour immune cells of a new patient
Liquid Biopsy Demo
One model built straight from raw sequencing reads, for RNA and DNA alike, with no gene list. Every score is on samples kept out of training.
Results last updated 2026-11-16 11:40 PST
How to read the chart. Each row is one fusion. Each column is one mix level: the percent of fusion RNA added to normal RNA. At each mix level, 3 libraries were made and sequenced. The number in a box tells how many of these 3 libraries contain the fusion. The last column shows that none of the 277 control samples contains any of the fusions. The two outlined fusions. KIF5B-RET is found in all 3 libraries that contain 5% fusion RNA. It is also found in 2 of the 3 libraries that contain only 1% fusion RNA. SLC45A3-BRAF is found in all 3 libraries that contain 5% fusion RNA. It is also found in 1 of the 3 libraries that contain only 1% fusion RNA. No other fusion is found in all 3 libraries at the 5% mix level.
All 16 fusions in the reference mix are found with no model training, 9 already at a 1% spike-in, and none in 277 control samples
P2G predicts the tumour DNA percent of 38 held-out libraries (R² 0.93)
Benefits of Rosa Bio Technology
- ROSA's "statistics first" Semore platform allows detection of genomic complexity missed by other methods
- Allows faster, cheaper, smarter genomics analysis
- Readily scalable
- Agnostic to nucleic acid type: DNA (WGS and targeted), RNA, short and long read, exome, non-coding regions, ctDNA, bisulfite, etc.
- Detects structure-based changes, not based on gene panels
- Can be used with tissue sample or liquid biopsy (plasma cfDNA)
- Software = AI ready
- Diverse applications: Dx, Tx, other
Panoptic. Faster. Cheaper.
Speed
Faster processing, lower overhead.
Accuracy
Assess all sequence variation in a sample with no bias.
Cost
High-efficiency analysis tools.
A Statistics-First Approach.
A new paradigm for analysis of nucleic acid sequence information. Unlike traditional methods, we require no reference genome for sequence alignment.
Our approach enables truly unbiased discovery, identifying patterns and variations that conventional tools simply cannot detect.
Why Statistics First
Our statistics-first approach analyzes raw data directly, eliminating reference genome bias and enabling detection of all genomic complexity.
White Papers
Read our white papers on the benefits of a statistics-first approach to genomic analysis.
Precision Medicine Applications
Patient stratification using sequence variation that predicts treatment response and disease progression.
Leadership
Julia Salzman
Founder
Associate Professor in the Department of Biomedical Data Science, and by courtesy in Biology and Statistics at Stanford University. A.B. in Mathematics from Princeton University magna cum laude and Ph.D. from Stanford University in Statistics. Developed statistical algorithms that discovered circular RNA and statistics-first genomic algorithms. Research funded by NIH, NSF, CZI. Recognized with Alfred P. Sloan Fellowship, McCormick-Gabilan Fellowship, and NSF CAREER Award.
Michael Rabson
Co-Founder & CEO
More than 25 years of experience in life sciences. Former partner at Wilson Sonsini Goodrich & Rosati for 15 years. Served as General Counsel of Maxygen (MAXY) and Cytokinetics (CYTK). Former patent examiner at USPTO focused on biotechnology. Member of the patent bar. Author of scientific publications in Science, Nature, PNAS. Ph.D. from Yale University and J.D. from Yale Law School.